Editorial: tofacitinib and biologics for moderate‐to‐severe ulcerative colitis—what is best in class? Authors’ reply

Publisher： John Wiley & Sons Inc

E-ISSN： 1365-2036|47|4|540-541

ISSN： 0269-2813

Source： ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol.47, Iss.4, 2018-02, pp. : 540-541

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Editorial: tofacitinib and biologics for moderate‐to‐severe ulcerative colitis—what is best in class?

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 47, Iss. 4, 2018-02 ,pp. : 539-540

John Wiley & Sons Inc

Access to resources Recommend Favorite

Systematic review with network meta‐analysis: comparative assessment of tofacitinib and biological therapies for moderate‐to‐severe ulcerative colitis

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 47, Iss. 4, 2018-02 ,pp. : 454-465

John Wiley & Sons Inc

Access to resources Recommend Favorite

Letter: infliximab in severe ulcerative colitis – is it useful for all patients? Authors’ reply

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 38, Iss. 11-12, 2013-12 ,pp. : 1413-1414

John Wiley & Sons Inc

Access to resources Recommend Favorite

Commentary: the effects of probiotics on barrier function and mucosal pouch microbiota during maintenance treatment for severe pouchitis in patients with ulcerative colitis – authors' reply

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 38, Iss. 11-12, 2013-12 ,pp. : 1406-1407

John Wiley & Sons Inc

Access to resources Recommend Favorite

Letter: stool adalimumab detection in ulcerative colitis and Crohn's disease – authors' reply

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 42, Iss. 2, 2015-07 ,pp. : 241-241

John Wiley & Sons Inc

Access to resources Recommend Favorite